J&J’s DePuy Synthes Unveils MatrixSternum for Chest Wall Stabilization

Johnson & Johnson (J&J) MedTech’s DePuy Synthes has introduced its MatrixSternum plate and screw fixation system in the US market. Designed to stabilize and secure the front part of the chest wall after procedures like open-heart and other chest surgeries, the MatrixSternum system is claimed to be three times stronger than the leading product in the market.

The system features 1.5mm-thin low-profile plates and multi-hole screw guides, aimed at reducing procedure time. DePuy Synthes, a leader in the US trauma fixation device market, holds nearly half of the market share in this segment.

The global orthopaedic device market is projected to grow from $52.5 billion in 2023 to over $70.5 billion by 2033, with the trauma fixation segment expected to increase from $7.5 billion to more than $8.7 billion in the same period, according to GlobalData.

Another notable chest fixation device is Able Medical’s Valkyrie RIB system, which received FDA approval in January 2024 for stabilizing and fixing chest fractures, including sternal reconstructive surgeries and trauma fractures.

DePuy Synthes has been actively expanding its portfolio, launching two additional devices in August 2024: the Trileap foot plating system and the Velys spine robotic assist system. The Trileap system is used for forefoot and midfoot reconstructive and trauma procedures, while the Velys system is a dual-use robotic and navigation platform designed for spinal fusion procedures.